|drug2508||Placebo (Methylcellulose) capsule Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy when there is no vaccine or treatment available for infectious diseases. In the latest viral epidemics, such as the Ebola outbreak in West Africa in 2014, the World Health Organization issued a document outlining a protocol for the use of whole blood or plasma collected from patients who have recovered from the Ebola virus disease by transfusion to empirically treat local infectious outbreaks
Description: Copies of COVID-19 per mlMeasure: Change in Viral Load Time: Days 0, 4, 7, 14 and 28
Description: Immunoglobulin G COVID-19 antibodiesMeasure: Change in Immunoglobulin G COVID-19 Titers Time: Days 0, 4, 7, 14 and 28
Description: Proportion of patients with Intensive Care Unit Admission requirement (days 7, 14 and 28)Measure: Intensive Care Unit Admission Time: Days 7, 14 and 28
Description: Days of Intensive Care Unit management (days 7, 14 and 28)Measure: Length of Intensive Care Unit stay Time: Days 7, 14 and 28
Description: Days of Hospitalization (days 7, 14 and 28)Measure: Length of hospital stay (days) Time: Days 7, 14 and 28
Description: Proportion of patients with mechanical ventilation (days 7, 14 and 28)Measure: Requirement of mechanical ventilation Time: Days 7, 14 and 28
Description: Days with mechanical ventilation (days 7, 14 and 28)Measure: Duration (days) of mechanical ventilation Time: Days 7, 14 and 28
Description: 1. Hospital discharge; 2. Hospitalization, not requiring supplemental oxygen; 3. Hospitalization, requiring supplemental oxygen (but not Noninvasive Ventilation/ HFNC); 4. Intensive care unit/hospitalization, requiring Noninvasive Ventilation/ HFNC therapy; 5. Intensive care unit, requiring extracorporeal membrane oxygenation and/or invasive mechanical ventilation; 6. Death. (days 7, 14 and 28)Measure: Clinical status assessed according to the World Health Organization guideline Time: Days 7, 14 and 28
Description: Proportion of death patients at days 7, 14 and 28Measure: Mortality Time: Days 7, 14 and 28
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports